Company intelligence / Profile preview
Selecxine
Seoul, South Koreaselecxine.com ↗
- Ownership
- Private
- Employees
- ~10
- Development stage
- Phase 1
01
Overview
Selecxine's lead asset SLC-3010 received IND clearance from MFDS for Phase 1/2 clinical trials in December 2022. SLC-3010 is a non-covalent conjugate of IL-2 and anti-hIL-2 antibody (TCB2) designed to preferentially stimulate immune cells related to anti-cancer activities rather than immune suppression[1][4].
- Therapeutic areas
- Oncology
- Modalities
- Monoclonal antibodiesImmunotherapeutics
- Industry
- Biotech
02
Drug pipeline
3 assets2 more assets in the full pipeline.
03
Partnerships
GenScript ProBio
Beyond the preview
Go deeper on Selecxine.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Selecxine.